MARUCCI, Gabriella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.558
EU - Europa 8.419
AS - Asia 5.508
SA - Sud America 758
AF - Africa 103
Continente sconosciuto - Info sul continente non disponibili 72
OC - Oceania 14
Totale 31.432
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.042
CN - Cina 2.494
RU - Federazione Russa 1.848
PL - Polonia 1.528
SG - Singapore 1.516
IT - Italia 1.299
DE - Germania 1.088
BR - Brasile 641
GB - Regno Unito 553
UA - Ucraina 505
SE - Svezia 501
HK - Hong Kong 449
CA - Canada 443
FR - Francia 378
FI - Finlandia 281
TR - Turchia 237
VN - Vietnam 210
KR - Corea 207
IE - Irlanda 118
IN - India 91
BE - Belgio 79
JP - Giappone 73
EU - Europa 71
AR - Argentina 59
MX - Messico 52
NL - Olanda 45
CZ - Repubblica Ceca 41
ZA - Sudafrica 41
BD - Bangladesh 35
ES - Italia 31
IR - Iran 31
AT - Austria 22
RO - Romania 22
EC - Ecuador 19
IQ - Iraq 19
AE - Emirati Arabi Uniti 17
PK - Pakistan 16
KE - Kenya 14
CH - Svizzera 13
ID - Indonesia 13
MA - Marocco 12
RS - Serbia 12
TW - Taiwan 12
JO - Giordania 11
LT - Lituania 11
PE - Perù 10
SA - Arabia Saudita 10
AU - Australia 9
IL - Israele 9
UZ - Uzbekistan 9
AZ - Azerbaigian 8
CO - Colombia 8
EG - Egitto 8
PY - Paraguay 8
TN - Tunisia 8
BG - Bulgaria 6
HR - Croazia 6
VE - Venezuela 6
AM - Armenia 5
GR - Grecia 5
LB - Libano 5
AL - Albania 4
BY - Bielorussia 4
CL - Cile 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
GE - Georgia 4
HN - Honduras 4
OM - Oman 4
PH - Filippine 4
CI - Costa d'Avorio 3
KZ - Kazakistan 3
NI - Nicaragua 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
TH - Thailandia 3
CR - Costa Rica 2
ET - Etiopia 2
KH - Cambogia 2
KW - Kuwait 2
LV - Lettonia 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
PA - Panama 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AS - Samoa Americane 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
GD - Grenada 1
GM - Gambi 1
Totale 31.414
Salva come PNG Salva come JPEG
Città #
Fairfield 1.492
Woodbridge 1.482
Dallas 1.304
Jacksonville 1.207
Ashburn 1.189
Warsaw 1.182
Chandler 948
Houston 812
Ann Arbor 709
Wilmington 687
Singapore 661
Seattle 636
Cambridge 543
Boardman 509
Hong Kong 430
Nanjing 407
Beijing 386
Kraków 331
Toronto 291
Los Angeles 254
Camerino 237
The Dalles 235
Istanbul 190
Columbus 186
San Mateo 185
Seoul 182
Düsseldorf 178
Tongling 167
Lawrence 163
Princeton 163
Dearborn 158
New York 154
Ogden 136
Moscow 133
Nanchang 125
London 123
Lachine 117
Dublin 116
Buffalo 114
Shanghai 107
Munich 105
Helsinki 104
Milan 95
Kunming 86
Guangzhou 84
Chicago 80
Brussels 75
San Diego 75
São Paulo 71
Council Bluffs 69
Shenyang 66
Ho Chi Minh City 64
Tianjin 63
Jiaxing 62
Hebei 61
Santa Clara 60
Tokyo 59
Hangzhou 45
Hanoi 43
Wuhan 39
Centro 37
Denver 37
Philadelphia 36
Venezia 36
Changsha 35
Ningbo 35
Orem 34
Frankfurt am Main 33
Rome 33
Dong Ket 31
Hefei 31
Redwood City 30
Turku 29
Brno 28
Brooklyn 28
Phoenix 28
Poplar 28
San Jose 28
Jinan 27
San Francisco 27
Stockholm 27
Chennai 26
Johannesburg 26
Venice 26
Boston 25
Orange 25
Norwalk 24
Perugia 24
Falls Church 23
Atlanta 22
Bremen 22
Yiwu 22
Nuremberg 21
Nürnberg 21
Verona 21
Zhengzhou 20
Belo Horizonte 19
Montreal 19
Rio de Janeiro 18
St Petersburg 18
Totale 21.115
Salva come PNG Salva come JPEG
Nome #
1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: Structure-affinity/activity relationship at α1-adrenoceptor subtypes and at 5-HT1A receptors. 582
1,2,4-Benzothiadiazine derivatives as alpha1 and 5-HT1A receptor ligands 561
“1,3 Oxathiolane Muscarinic Ligands Modified at the Cationic Head”. 524
1,3-Dioxolane-based ligands as a novel class of alpha(1)-adrenoceptor antagonists 500
1,3-Dioxolane-based ligands as rigid analogues of Naftopidil: structure-affinity/activity relationships at alpha1 and 5-HT1A receptors. 493
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 405
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 383
Overview on Radiolabel-Free in Vitro Assays for GPCRs 379
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 355
Pharmacological characterization of the GPR17 receptor dual profile 355
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 340
The G Protein-Coupled Receptor GPR17: Overview and Update 326
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 325
GPR17 receptor modulators and their therapeutic implications: review of recent patents 278
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 273
“Synthesis and α-Adrenoreceptor Blocking Properties of Phenoxybenzamine-Related (2-Chloroethyl)-(2,3-dihydrobenzo-[1,4] dioxin-2-ylmethyl)-(2-phenoxyethyl) Amines”. 273
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 262
Synthesis and pharmacological profile of a series of 1-substituted-2-carbonyl derivatives of diphenidol: novel M4 muscarinic receptor antagonists 260
Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in Δ16HER2 transgenic mice 258
4-(4-Fluorobenzoyl)-1-[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]piperidine and its derivatives: synthesis and affinity at 5-HT2A, 5-HT2B and 5-HT2c serotonin receptors 252
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 252
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 252
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 249
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 248
Synthesis and antimuscarinic activity of derivatives of 2-substituted-1,3-dioxolanes 241
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 239
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 234
“New Pyridazinones: Synthesis and Correlation Between Structure and α-Blocking Activity”. 233
Synthesis and alpha1-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin 231
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 226
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 222
5HT2B receptor antagonists: a probe for spotting the pharmacophore 216
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 214
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 212
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 212
Synthesis and structure-activity relationships of novel arylpiperazines as potent antagonists of α1-adrenoceptor 212
Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications. 210
New sensible method to quantize the intestinal absorption of receptor ligands 210
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 210
Benzimidazole, benzoxazole and benzothiazole derivatives as 5HT(2B) receptor ligands. Synthesis and preliminary pharmacological evaluation 209
14th Camerino-Noordwijkerhout Symposium - Ongoing Progress in Receptor Chemistry 206
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 206
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 202
(+)-Cyclazosin derivatives as α1-adrenoceptor antagonists 201
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 201
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 200
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 200
Antiviral properties of deazaadenine nucleoside derivatives 200
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 198
Determination of Muscarinic Agonist Potencies at M1 and M2 Muscarinic Receptors in a Modified Pithed rat Preparation 197
(+)-Cyclazosin, a selective alpha1B-adrenoceptor antagonist: Functional evaluation in rat and rabbit tissues 197
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 196
Simplified analogues of Ritanserin and their affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors 196
Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives 196
(2,2-Diphenyl-[1,3]oxathiolan-5-ylmethyl)-(3-phenyl-propyl)-amine: a Potent and Selective 5-HT1A Receptor Agonist 195
Analogues of Prazosin That Bear a Benextramine-Related Polyamine Backbone Exhibit Different Antagonism toward alpha1-Adrenoceptor Subtypes 195
"[4-[[N-(3-Chlorophenyl)carbamoyl]-2-butynyl]-trimethylammonium (McN-A-343)-Related Compounds. Effect of the Butynyl Chain Inclusion into an Aromatic Unit of the Potency for Muscarinic Receptors 195
Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 3. Effect of inserting the tetraamine backbone into a macrocyclic structure 194
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 194
Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine 194
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes 193
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 193
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 193
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 192
Synthesis and pharmacological characterization of enantiomerically pure muscarinic agonists: difluoromuscarines 191
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 190
Structure-Activity Relatioships Among Novel Phenoxybenzamine-Related Beta-Chloroethylamines. 190
Chiral analogues of (+)-cyclazosin as potent α1B-adrenoceptor selective antagonist 190
Adenosine receptor modeling: what does the A2A crystal structure tell us? 189
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 189
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine 188
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 187
Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds 185
Synthesis and antagonistic activity at muscarinic receptor subtypes of some derivatives of diphenidol 185
“Dialkylaminoalkyl Esters of 2,2 Diphenyl-2-Alkylthioacetic Acids: A New Class of Potent and Functionally Selective Muscarinic Antagonists”. 185
Design, synthesis and muscarinic activity of deoxamuscarine-related derivatives 185
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 185
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 184
Synthesis and α1-antagonist activity of derivatives of 4-chloro-5-{4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl}-3(2H)-pyridazinone 184
“N,N-diethylaminoethanol and N-methyl-4-piperidinol Esters of 2,2-diphenyl-2-Ethylthioacetic Acid as Potent and Selective Muscarinic Antagonist”. 183
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure 177
“Pharmacological Characterization of Muscarinic Receptor Subtypes in Rabbit Isolated Tissue Preparations” 177
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 177
Synthesis and pharmacological characterization of chiral pyrrolidinylfuran derivatives: The discovery of new functionally selective muscarinic agonists 176
Molecular modulation of muscarinic antagonists. Synthesis and affinity profile of 2,2-diphenyl-2-ethylthio-acetic acid esters designed to probe the binding site cavity. 176
“Synthesis and Pharmacological Evaluation of Enantiomerically Pure 4-Deoxy-4-Fluoro-Muscarines”. 176
“Synthesis and Pharmacological Activity of Some New Pyridazinones”. 174
16th Camerino-Noordwijkerhout Symposium - An Overview of Receptor Chemistry 173
“Synthesis and α1-Antagonist Activity of New Prazosin-and Benextramine-Related Tetraamine Disulfides”. 173
Structure-affinity/activity relationships of 1,4-dioxa-spiro[4.5]decane based ligands at α1 and 5-HT1A receptors 173
Synthesis and pharmacological characterization of new chiral derivatives of muscarine and allo-muscarine 171
Molecular modulation of muscarinic antagonists. Synthesis and pharmacological profile of 2,2-diphenyl-2-ethylthioacetic and 3,3-diphenyl-3-ethylthiopropionic acid derivatives characterized by a dipeptide spacer. 171
Searching for cyclazosin analogues as alfa1B-adrenoceptor antagonists 170
Structure-Activity Relationships of Methoctramine-Related Polyamines as Muscular Nicotinic Receptor Noncompetitive Antagonists. 2. Role of Polymethylene Chain Lengths Separating Amine Functions and of Substituents on the Terminal Nitrogen Atoms. 169
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 168
“Novel and Highly Selective Postsynaptic α-Adrenoreceptor Antagonists: Synthesis and Structure-Activity Relationships of Alkane-Bridged [4-(phenoxyethyl)-1-piperazinyl]-3 (2H)-pyridazinones”. 168
Alpha(2)-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole 165
Highly chiral muscarinic ligands: The discovery of (2S,2 ' R,3 ' S,5 ' R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M-2 partial agonist 164
Polyamines may modulate both G protein-coupled receptors and G proteins. 164
SAR Studies on the Potent and Selective Muscarinic Antagonist 2-Ethylthio-2,2-diphenylacetic Acid N,N-Diethylaminoethyl Ester 164
Totale 23.066
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.443
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.443
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.504 0 0 0 0 0 362 629 95 318 188 556 356
2021/20221.977 189 478 39 103 99 65 100 154 145 228 147 230
2022/20232.322 257 120 84 384 260 312 13 146 385 121 170 70
2023/20241.769 252 102 112 59 71 115 86 103 198 70 63 538
2024/20255.716 203 146 485 264 159 340 639 1.449 429 403 399 800
2025/20265.375 534 593 1.706 1.137 959 446 0 0 0 0 0 0
Totale 31.913